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Summary
Background: Chemotherapy-induced alopecia (CIA) is probably one of the most
shocking aspects for oncological patients and underestimated by physicians. Among
hair loss risk factors, there are treatment-related aspects such as drug dose, admin-
istration regimen, and exposure to X-rays, but also patient-related characteristics. To
the best of our knowledge, no guidelines are available about CIA management.
Aims and methods: With this study, based on literature background and our clinical
experience, we would like to propose a list of actions in order to estimate the risk
of hair loss before starting chemotherapy and to manage this condition before, dur-
ing, and after drug administration and to create a sort of practical guide for derma-
tologists and oncologists.
Results and conclusion: There is an urgent need for prospective studies to clarify
the mechanistic basis of alopecia associated with these drugs and consequently to
design evidence-based management strategies.
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1 | BACKGROUND
Chemotherapy-induced alopecia (CIA) is probably one of the most
shocking aspects for oncological patients and underestimated by
physicians. It negatively influences body image, sexuality, and self-
esteem, so that up to 8% of patients decide to refuse chemotherapy
if there is the risk of hair loss.1
Its incidence is estimated to be 65%, even if the prevalence and
severity of hair loss are related to the drug category and to the num-
ber of the administered drugs. With antimicrotubule agents, it is
reported more than 80% incidence of alopecia, 60%-100% with
topoisomerase inhibitors, >60% with alkylators, and 10%-50%
with antimetabolites (Table 1). Polychemotherapy is associated with
higher incidences compared to monotherapy.2
Among hair loss risk factors, there are treatment-related aspects
such as drug dose, administration regimen, and exposure to X-rays,
but also patient-related features such as age, comorbidities, the
presence of any type of alopecia (more frequently androgenetic
alopecia), and nutritional and hormonal status.3
About hair-shaft shedding, it can be reached out from days to
weeks after starting chemotherapy, and different shedding patterns
can be observed (dystrophic anagen effluvium and telogen efflu-
vium). Frontal or occipital hairlines are more frequently involved,
suggesting that the affected areas seem to be selective.
Among factors that may influence the shedding pattern, the
mitotic activity of the hair follicle in the moment of the insult is
probably the more important.2 The main targets of anticancer drugs
are the matrix keratinocytes, which are highly proliferative during
anagen phase, and their pigmentary system. These structures are
very sensitive to toxins and drugs, which can easily lead them to
rapid apoptosis.2,3 Catagen and telogen are not affected because
they are mitotically inactive phases, but when hair is in late anagen
phase, characterized by a lower mitotic rate, chemotherapy acceler-
ates the normal transition to telogen.2,3
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If we consider that up to 90% of scalp hairs are normally anagen
phase, it is easy to explain why the scalp is the most frequent
affected area, whereas hairs of the beard, eyebrows, and eyelashes,
as well as axillary and pubic regions, are affected depending on the
percentage of hairs in anagen.
This kind of alopecia is generally reversible and hair usually
regrows after 3-6 months, even if temporarily the new hair may
show changes in color and/or texture. Although rare, cases of
permanent alopecia, with severely retarded or without hair regrowth,
are reported to be associated with high-dose chemotherapy or with
busulfan and cyclophosphamide administration, and it is probably the
consequence of a damage to hair follicle stem cells.2-4
We consider it is worthwhile to mention alopecia associated with
aromatase inhibitors. The agents, such as letrozole and anastrozole,
are associated with a recession of the frontal and parietal hairlines,
diffuse hair loss, and miniaturization of follicles in the frontotemporal
area, mimicking a typically female androgenetic alopecia (FAGA) with
male pattern. The pathogenic mechanism of this type of hair loss
seems to be associated with the decrease in estrogen synthesis.
Estrogens are potent hair growth modulators and hair protective fac-
tors and derive from the conversion of androstenedione to estrone
and testosterone to estradiol by aromatase (P450arom), the levels of
which in frontal and occipital follicles of women are higher than in
the same areas of men. The block of this enzyme induces a relative
enhancement in the activity of 5a-reductase which leads to a rela-
tive increase in amount of testosterone available for conversion to
DHT.5
To the best of our knowledge, no guidelines are available about
CIA management. The aim of this study was to propose a list of
actions in order to estimate the risk of hair loss before starting
chemotherapy and to manage this condition before, during, and after
drug administration and to create a sort of guidelines for dermatolo-
gists and oncologists.
2 | PRECHEMOTHERAPY MANAGEMENT
Nowadays, no guidelines are available about prechemotherapy man-
agement. To estimate the risk of hair loss in a single patient before
starting the treatment, it could be interesting to create a guide for
dermatologists to analyze scalp condition. In our opinion, the follow-
ing aspects should be evaluated.
First of all, patient selection is fundamental. Considering the bet-
ter known therapeutic protocols and so the major knowledge about
their side effects, in this study we considered only patients with
solid tumor and not patients with hematological neoplasia.
Anamnestic data should be collected: Previous scalp diseases
(psoriasis, seborrheic dermatitis, and atopic dermatitis, among the
most frequent) and autoimmune diseases or a family history of
alopecia could reveal a tendency to some types of alopecia or a sub-
clinical disease that could become evident after chemotherapy. Obvi-
ously the drug protocol that will be administered is crucial to
estimate the risk of hair loss.
In addition, some blood examinations could be requested. As is
known, blood levels of hemoglobin and iron, thyroid hormones, and
vitamin D could be associated with hair loss,6-9 so that it may be
desired to have sufficient blood levels of these substances before
starting any type of anticancer drugs.10
Scalp dermoscopy (trichoscopy) is another rapid and noninvasive
method that may help to unveil several scalp diseases or some
types of alopecia that could be present even before chemother-
apy.11 Trichoscopy can reveal an early stage of androgenetic alope-
cia, an alopecia areata incognita, or some kind of cicatricial alopecia
such as a lichen planopilaris or a discoid lupus erythematosus that
can lead to a permanent alopecia even without chemotherapy, but
that could be accelerated and could get worse by anticancer
drugs.12
Pull test and trichogram together with trichoscopy could also be
a useful tool to evaluate hair condition at T0 and to know whether
pathological mechanisms are already acting. Moreover, trichogram
could show hair cycle phase and therefore hair’s susceptibility to
chemotherapeutic agent damage.
All these evaluations can be considered to estimate the risk of
hair loss after chemotherapy and to better manage alopecia during
and after drug administration.
The following steps should be the prescription of drugs that
could prevent hair loss. Even if no drugs are actually approved for
this goal, some molecules have been studied.
Soref et al.13 studied the role of topical epinephrine or
norepinephrine in preventing radiotherapy- and chemotherapy-
induced alopecia in 10-day-old rats with good results and no
side effects. This action of vasoconstrictors could probably be
explained by a work of Rathman-Josserand et al.14 that
hypothesized that the induction of hypoxia signaling could help
hair follicle stem cells to maintain their function and hence
prevent alopecia or at least favor neogenesis; moreover, vaso-
constriction may reduce the drug dose that reaches the hair
follicle, just as scalp cooling acts. When compared to scalp
cooling, vasoconstrictors have the advantage of an easier
administration, so that they can be applied more than once a
day even before starting chemotherapy, ensuring both a pre-
venting and a long-lasting effect; meanwhile, scalp cooling just
acts during drug infusion.
On the basis of this experience, we are trying to use a galenic
hydrogel, composed of ephedrine 0.5% and naphazoline 0.125%, in
our patients before the beginning of chemotherapy. We think that
the use of these kinds of vasoconstrictors could be a useful tool to
TABLE 1 Incidence of alopecia associated with the main
chemotherapeutic drug categories
Drug category Incidence of alopecia
Antimicrotubule agents 80%
Topoisomerase inhibitors 60%-100%
Alkylators >60%
Antimetabolites 10%-50%
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prevent chemo-induced alopecia, even if more studies are
necessary.
3 | DURING-CHEMOTHERAPY
MANAGEMENT
Implementation of gentle hair care strategies should be adopted
throughout and after chemotherapy. A soft brush should be used, to
avoid additional traumas, and hair should be washed only as often as
necessary using a gentle shampoo. Cutting hair short or shaving hair
is not necessary, but it could be more comfortable.
To help patients to deal with this condition and to protect the
scalp from sun and cold exposure can be used a wig. To improve
patients’ psychological condition and allow them to use their own
hair, an analogous wig could be used, obtained by cutting patients’
hair and implanting them on a prosthetic support.2
Another instrument proposed as a preventive therapy for alope-
cia is scalp cooling. Actually, its mechanism is not well known, but it
probably works through vasoconstriction, decreasing local concentra-
tion of chemotherapy and cellular uptake at the hair follicle, and
reducing metabolic uptake. A recent meta-analysis reported that this
method significantly reduces CIA15 and patients’ compliance is good,
even if some cases of headache and uncomfortable feelings could be
associated1–3,16–18 as reported by Betticher et al.17 Best results have
been described for alopecia induced by doxorubicin, epirubicin, and
docetaxel, while it should be avoided in hematological malignancies
because of the risk of scalp skin metastasis.2,3
Many drugs have been used to avoid chemo-induced alopecia,
but no one has been approved.
In our opinion, the combination of topical steroids and topical
vasoconstrictors could be a useful tool to prevent a massive damage
to hair follicle, and in particular to hair follicle stem cells, with the
goal to prevent a permanent alopecia.
4 | POSTCHEMOTHERAPY MANAGEMENT
To accelerate the regrowth after chemotherapy, 2% topical minoxidil
is the best treatment. Its mechanism of action is not already known,
but several hypotheses have been proposed, such as opening of
potassium channels by its sulphated metabolite, stimulation of ker-
atinocyte proliferation, inhibition of collagen synthesis and produc-
tion, and stimulation of vascular endothelial growth factor (VEGF)
and prostaglandin synthesis. It was demonstrated that minoxidil pro-
longs the duration of anagen and enlarges miniaturized follicles.19
It must be applied twice a day on the involved areas for at least
6 months. It has been demonstrated to reduce the severity and
duration of alopecia.1-3
Also antioxidant agents could have a role in the postchemother-
apy period. N-acetylcysteine, an analog and precursor of glutathione,
has been demonstrated to be capable of protecting neonatal rats
from cyclophosphamide CIA and adult mice from doxorubicin CIA
both when administered topically and parentally.20,21 Speaking of
which it is necessary to pay attention because recently it has been
reported that some kind of tumor may benefit from the reduction of
oxidative stress caused by antioxidant, and this effect is obviously
more important when they are parentally administered.
Another agent that has been used to facilitate hair regrowth
after chemotherapy is calcitriol (1,25-dihydroxyvitamin D3), which
was considered the most promising agent for treating CIA.22,23 It has
multiple effects on keratinocytes: inhibition of DNA synthesis, which
causes cell cycle arrest at the G0/G1 interphase, inducing differenti-
ation; inhibition of Ki67 expression, a marker of cycling cells; and
inhibition of the growth of multiple other cell types.10,22-31 Hidalgo
et al.32 also referred to contact dermatitis associated with 1,25-dihy-
droxyvitamin D3, and therefore, it must be used with caution in par-
ticular if applied topically.
5 | TARGET THERAPY-INDUCED
ALOPECIA
What is exposed before is related to “classic” anticancer drugs that
are better known. But several molecularly targeted anticancer thera-
pies have been developed, with an impressive clinical benefit in
terms of efficacy and survival rates, but also with new or different
side effects. These new drugs may also cause alopecia, even if its
characteristics are different from which we described for conven-
tional chemotherapies. Belum reported an overall incidence of 14.7%
of alopecia associated with these drugs (lowest for bortezomib and
highest for vismodegib).33
In contrast to conventional chemotherapy, where the mechanism
is predominantly nonselective cytotoxicity, the mechanisms at the
basis of hair loss induced by these drugs are poorly understood.3
The primary target inhibited, type of the drug, variations in the tar-
get spectrum of inhibition, molecular cross talk between pathways,
and the inherent role of these molecules in hair follicle biology may
all be involved in the pathogenesis of hair loss.
These drugs selectively target various oncogenic molecules/path-
ways such as SMO, VEGFR, and MAPK, but the incidence of alope-
cia varies even among drugs acting on the same primary molecular
target. Various pathogenic mechanisms may be involved considering
two aspects: First, each one of these drugs often targets multiple
other pathways, and second, the spectrum of inhibition and receptor
affinity might vary from a drug to another.33
Concerning Shh pathway in hair follicle biology and epidermal
homeostasis, murine studies have shown that its inhibition in the
skin can lead to reversible alopecia and arrest of hair growth in the
telogen phase.34 This explains vismodegib-induced alopecia.
Inhibition of the EGFR is associated with follicular disintegration
accompanied by inflammation because of its crucial role in anagen-
catagen transition.35-37
The onset and pattern of alopecia are not well described. The
alopecia may be frontal (androgenetic-like), diffuse, or patchy, and it
is generally nonscarring38,39; pruritus may also be present. In some
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cases, scarring alopecia/folliculitis decalvans with pain and infection
may develop.40,41
The onset after the beginning of treatment may range from
2 weeks to months and resolve within 1-6 months after drug dis-
continuation; the quality of hair and rate of regrowth may also be
affected.42
With the expanding use of targeted agents, there is an urgent
need for prospective studies to clarify the mechanistic basis of
alopecia associated with these drugs and consequently to design evi-
dence-based management strategies.
Moreover, these conditions should be treated among several
specialists, to reduce evaluation times and simplify their manage-
ment. The dermatologist has a crucial role in every aspect of the
treatment phase and should work together with the oncologist in
taking care of these patients.
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